International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 8, Issue 2 (March-April 2026) Submit your research before last 3 days of April to publish your research paper in the issue of March-April.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 8 Issue 2
March-April 2026

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Utilization pattern of dipeptidyl peptidase IV inhibitors in diabetes mellitus patients

Author(s) Ms. Shaik Khamar E Azam, Dr.V.Satyanarayana, B.Lalitha Bai, T.Venu, Sk.Mahaboob Subhani
Country India
Abstract Type 2 diabetes mellitus is a rapidly growing global health concern, with its prevalence projected to increase significantly in the coming years. The disease is linked to multiple long-term complications that affect various organ systems, contributing to increased morbidity, mortality, and healthcare burden worldwide. Due to its multifactorial nature, management strategies for type 2 diabetes involve a wide range of pharmacological options targeting different underlying mechanisms, such as improving insulin secretion, enhancing insulin sensitivity, delaying carbohydrate absorption, and promoting glucose excretion.

Among these therapeutic options, DPP-4 inhibitors, commonly referred to as “gliptins,” have gained considerable importance. These oral agents act by inhibiting the DPP-4 enzyme, thereby prolonging the activity of incretin hormones like glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This results in improved glucose-dependent insulin release and reduced glucagon secretion, helping to achieve better glycemic control.

Over the past decade, DPP-4 inhibitors have been widely used due to their favorable safety profile and ease of administration. This review highlights their mechanism of action, clinical utility, and overall role in the comprehensive management of type 2 diabetes mellitus.
Keywords DPP-4 inhibitors; gliptins; type 2 diabetes mellitus; HbA1c; incretin; sitagliptin; vildagliptin; saxagliptin; linagliptin; alogliptin.
Field Medical / Pharmacy
Published In Volume 8, Issue 2, March-April 2026
Published On 2026-04-12
View / Download PDF File

Share this



E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 8 Isu 2Cover Page Vol 8 Isu 1Cover Page Vol 7 Isu 6

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9687-828-838 editor@ijfmr.com
Powered by Sky Research Publication and Journals